Pharmaceuticals

MGC Pharmaceuticals Enters Partnership with Sciensus Rare for Distribution of Cannabinoids to Treat Refractory Epilepsy, Dementia and Alzheimer's in the EU and UK

LONDON, April 5, 2022 /PRNewswire/ -- MGC Pharmaceuticals Ltd. (LSE: MXC, ASX: MXC, OTC:MGCLF), a European based bio-pharma company specializing in the production and development of phytomedicines, has signed an exclusive distribution agreement withSciensus Rare

2022-04-05 14:00 3546

TraceLink Announces Product Availability Intelligence, Enabling Manufacturers to Predict Drug Shortages up to 90 Days in Advance with Greater Than 80% Accuracy

Opus™, the operating platform for Industry 4.0, provides the infrastructure to predict drug shortages by applying Artificial Intelligence to analyze the movement of more than 30 billion products tracked within the world's largest Healthcare and Life Sciences network. BOSTON, April 5, 2022 /PRNew...

2022-04-05 13:00 2979

Indonesia's G20 Health Working Group (HWG) Meeting Series Work Towards Standardization of Global Health Protocols

JAKARTA, April 5, 2022 /PRNewswire/ -- Assuming the presidency in the upcoming G20 summit,Indonesia has begun the Health Working Group (HWG) meeting series that took place on28-30 March 2022 in Yogyakarta, Indonesia. Indonesia's Ministry of H...

2022-04-05 09:00 5882

Indonesia's Ministry of Health Discussed a Universal Vaccine Passport and Verifier for International Travelers

JAKARTA, April 4, 2022 /PRNewswire/ -- Assuming the presidency in the upcoming G20 summit,Indonesia has begun the Health Working Group (HWG) meeting series that took place on28-30 March 2022 in Yogyakarta, Indonesia. Indonesia's Ministry of H...

2022-04-04 23:35 2660

Sirnaomics Doses First Subject in Phase I Clinical Trial of STP707 for the Treatment of Liver Fibrosis in Primary Sclerosing Cholangitis

HONG KONG, April 4, 2022 /PRNewswire/ -- Sirnaomics Ltd. ("Sirnaomics," stock code: 2257.HK), a leading biopharmaceutical company in discovery and development of RNAi therapeutics, announced today dose administration for the first subject in a U.S. Phase I clinical tr...

2022-04-04 21:31 4400

Ascletis Announces Completion of First Sale of Its Ritonavir Tablets in Zhejiang Province

HANGZHOU, China and SHAOXING, China, April 4, 2022 /PRNewswire/ -- Ascletis Pharma Inc. (HKEX: 1672) today announces that the first sale of its ritonavir tablets inZhejiang Province has been completed. On April 3, 2022, Ascletis' distributor, Zhejiang Int'l Medicine Co., Ltd. ("Zhejiang Int'l"),...

2022-04-04 17:10 4210

Telix, GMS and Monash Awarded $23M Federal Government Funding as part of $71M Australian Precision Medicine Enterprise (APME) Project

MELBOURNE, Australia, April 4, 2022 /PRNewswire/ -- Telix Pharmaceuticals Limited (ASX: TLX, Telix, the Company) today announces that it is part of a $71.2 million Australian Precision Medicine Enterprise (APME) Project, which has been awarded$23 million in Federal Government grant funding under t...

2022-04-04 09:13 4658

CanSinoBIO's COVID-19 mRNA Vaccine Receives Approval of Clinical Trial Application in China

TIANJIN, April 4, 2022 /PRNewswire/ -- CanSino Biologics Inc. ("CanSinoBIO" of "the Company") (SSE: 688185, HKEX: 06185) today announced that the National Medical Products Administration ofChina ("NMPA") granted approval for the clinical trial application of its COVID-19 mRNA vaccine inChina. Pr...

2022-04-04 08:30 6103

Innovent Releases Results of a Phase 3 Clinical Study of IBI306 (PCSK-9 inhibitor) in Chinese Patients with Heterozygous Familial Hypercholesterolemia at the American College of Cardiology Annual Congress 2022

SAN FRANCISCO and SUZHOU, China, April 4, 2022 /PRNewswire/ -- Innovent Biologics, Inc. (Innovent) (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high quality medicines for the treatment of oncology, metabolic, autoimmune and other major dise...

2022-04-04 08:00 4795

Commercial Launch: Illuccix® Now Available to Order in the United States

MELBOURNE, Australia and INDIANAPOLIS, April 4, 2022 /PRNewswire/ -- Telix Pharmaceuticals Limited (ASX: TLX, Telix, the Company) announces that its prostate cancer imaging agent, Illuccix® (kit for preparation of gallium Ga 68 gozetotide), also known as68Ga-PSMA-11 injection, is now commercially...

2022-04-04 07:06 3368

Ascletis Announces Submission of Marketing Authorization Application for Ritonavir in Hong Kong

HANGZHOU and SHAOXING, China, April 3, 2022 /PRNewswire/ -- Ascletis Pharma Inc. (HKEX: 1672) today announces that it has submitted the marketing authorization application for ritonavir (100 mg film-coated tablet) in the Hong Kong Special Administrative Region ofthe People's Republic of China ("H...

2022-04-03 18:20 5224

JW Therapeutics Announces Receipt of Breakthrough Therapy Designation for Carteyva® in Mantle Cell Lymphoma in China

SHANGHAI, April 3, 2022 /PRNewswire/ -- JW Therapeutics (HKEx: 2126), an independent, innovative biotechnology company focused on developing, manufacturing and commercializing cell immunotherapy products, announced that the Center for Drug Evaluation (CDE) of the National Medical Products Admini...

2022-04-03 18:05 5461

Dada's JDDJ in action to guarantee medical supply and online health consultation with pharmaceutical partners

SHANGHAI, April 2, 2022 /PRNewswire/ -- As a number of cities in China are ramping up anti-epidemic measures, more consumers rely on online-to-offline services to purchase much-needed medications. JDDJ, one ofChina's largest local on-demand retail platforms operated by Dada Group (Nasdaq: DADA), ...

2022-04-02 20:53 4155

Peijia Medical Announces 2021 Annual Results

Dual Engines Promote Commercialization Total Revenue Increased by 253.2% HONG KONG, April 2,  2022 /PRNewswire/ -- Peijia Medical Limited ("Peijia Medical" or the "Company", together with its subsidiaries, the "Group", stock code: 9996), a leading player in the high-growth transcatheter valve th...

2022-04-02 00:06 11357

Pharming Announces Positive Data from Phase II/III Leniolisib Trial Presented at Clinical Immunology Society 2022 Annual Meeting

LEIDEN, Netherlands, April 1, 2022 /PRNewswire/ -- Pharming Group N.V. ("Pharming" or "the Company") (EURONEXT Amsterdam: PHARM/Nasdaq: PHAR) announces new data from the pivotal Phase II/III trial of leniolisib for the treatment of activated phosphoinositide 3-kinase delta (PI3Kδ) syndrome (APDS)...

2022-04-01 23:45 7301

Zhongze Therapeutics Announces Successful Completion Of The First-In-Human Dose Escalation Study of ZZ6398 in Healthy Volunteers

SHANGHAI, April 1, 2022 /PRNewswire/ -- Zhongze Therapeutics, a clinical stage biotech company focused on the discovery, development and commercialization of innovative and transformative therapies for both psychiatric and neurological disorders announced today the successful completion of the fi...

2022-04-01 16:55 2157

Akeso Reported 2021 Annual Results

Penpulimab Started Commercialization and Cadonilimab Filed for NDA HONG KONG, April 1, 2022 /PRNewswire/ -- Akeso, Inc. (9926.HK) ( "Akeso" ), a China-based biopharmaceutical company focusing on the development and commercialization of innovative therapeutic antibodies for Oncology & Immunology,...

2022-04-01 13:44 25675

Zhimeng Biopharma Announces Dosing of First Subject in First-in-Human Phase -- Clinical Trial of CB06

SHANGHAI, March 31, 2022 /PRNewswire/ -- Shanghai Zhimeng Biopharma, Inc. ("Zhimeng"), an innovation-driven biopharmaceutical company focused on the development of innovative drugs for the treatment of chronic hepatitis B and central nervous system diseases, announced dosing of the first particip...

2022-03-31 23:40 2264

Aceemzyme Co., Ltd., challenging to new drug of brain diseases with recombinase-based ginsenoside Rh2 (s) mass production technology…

- Under development of ginsenoside Rh2(s) mass production technology… - "Enhanced production of ginsenoside Rh2(S) from PPD-type major ginsenosides using BglSk cloned fromSaccharibacillus kuerlensis together with two glycosidase in series" SOUTH KOREA, Seoul, March 31, 2022 /PRNewswire/ -- Ginse...

2022-03-31 21:00 1439

I-Mab Announces Voluntary Lock-ups by Key Shareholders and Senior Management for Long-Term Commitment

SHANGHAI and GAITHERSBURG, Md., March 31, 2022 /PRNewswire/ -- I-Mab (the "Company") (Nasdaq: IMAB), a clinical-stage biopharmaceutical company committed to the discovery, development, and commercialization of novel biologics, today announced that the Company's key shareholders including CBC Grou...

2022-03-31 20:00 2002
1 ... 311312313314315316317 ... 349